Brain tumors are the most common solid neoplasms of childhood, but they are very rarely reported in children with Down Syndrome (DS), who develop more commonly different types of malignancies. In particular, we hereby report the case of an 8-years-old child with DS that presented to our attention for neurological and endocrinological issues. Brain imaging revealed the presence of a mass that was partially resected revealing a histological diagnosis of Pleomorphic Xanthoastrocytoma (PXA), a rare WHO grade II tumor extending from the diencephalic region into the surrounding brain tissue. These tumors can harbor the BRAF mutation p.V600E, targetable by the specific inhibitor Vemurafenib. After confirming the presence of the mutation in the tumor, the patient was treated with Vemurafenib. The treatment proved to be effective, leading to a partial response and a stabilization of the disease. Usually, in patients with DS a reduction of the dose of chemotherapeutic drugs is necessary. Vemurafenib was instead well-tolerated as the only observed adverse effect was grade I skin toxicity. This is, to our knowledge, the first case of a PXA reported in a child with DS and the first DS patient treated with Vemurafenib.

Vemurafenib treatment of pleomorphic xanthoastrocytoma in a child with Down syndrome / Petruzzellis, G.; Valentini, D.; Del Bufalo, F.; Ceglie, G.; Carai, A.; Colafati, G. S.; Agolini, E.; Diomedi-Camassei, F.; Corsetti, T.; Alessi, I.; Mastronuzzi, A.; Locatelli, F.; Cacchione, A.. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - 9:APR(2019). [10.3389/fonc.2019.00277]

Vemurafenib treatment of pleomorphic xanthoastrocytoma in a child with Down syndrome

Locatelli F.;
2019

Abstract

Brain tumors are the most common solid neoplasms of childhood, but they are very rarely reported in children with Down Syndrome (DS), who develop more commonly different types of malignancies. In particular, we hereby report the case of an 8-years-old child with DS that presented to our attention for neurological and endocrinological issues. Brain imaging revealed the presence of a mass that was partially resected revealing a histological diagnosis of Pleomorphic Xanthoastrocytoma (PXA), a rare WHO grade II tumor extending from the diencephalic region into the surrounding brain tissue. These tumors can harbor the BRAF mutation p.V600E, targetable by the specific inhibitor Vemurafenib. After confirming the presence of the mutation in the tumor, the patient was treated with Vemurafenib. The treatment proved to be effective, leading to a partial response and a stabilization of the disease. Usually, in patients with DS a reduction of the dose of chemotherapeutic drugs is necessary. Vemurafenib was instead well-tolerated as the only observed adverse effect was grade I skin toxicity. This is, to our knowledge, the first case of a PXA reported in a child with DS and the first DS patient treated with Vemurafenib.
2019
BRAF V600E mutation; brain tumor; Down syndrome; pleomorphic xanthoastrocytoma; vemurafenib
01 Pubblicazione su rivista::01i Case report
Vemurafenib treatment of pleomorphic xanthoastrocytoma in a child with Down syndrome / Petruzzellis, G.; Valentini, D.; Del Bufalo, F.; Ceglie, G.; Carai, A.; Colafati, G. S.; Agolini, E.; Diomedi-Camassei, F.; Corsetti, T.; Alessi, I.; Mastronuzzi, A.; Locatelli, F.; Cacchione, A.. - In: FRONTIERS IN ONCOLOGY. - ISSN 2234-943X. - 9:APR(2019). [10.3389/fonc.2019.00277]
File allegati a questo prodotto
File Dimensione Formato  
Petruzzellis_Vemurafenib_2019.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 3.16 MB
Formato Adobe PDF
3.16 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1480032
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 9
social impact